News Organon & Co.

Equities

OGN

US68622V1061

Real-time Estimate Cboe BZX Other stock markets 11:15:55 2024-04-24 am EDT			5-day change	1st Jan Change
18.34 ^USD	-0.94%		+3.27%	+27.98%

Apr. 09	Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	MT
Apr. 08	Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	Apr. 09	MT
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	Apr. 08	MT
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	Apr. 08	BU
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	Apr. 08	BU
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	Mar. 19	MT
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	Mar. 08	AQ
Philips: new CFO in October	Feb. 28	CF
New York attorney general urges stronger safety warning on asthma drug Singulair	Feb. 23	RE
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary	Feb. 21	AQ
Organon's Hadlima Chosen by VA as Substitute for Humira	Feb. 20	MT
Goldman Sachs Adjusts Price Target on Organon to $18 From $16, Keeps Neutral Rating	Feb. 20	MT
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	Feb. 20	BU
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies	Feb. 20	AQ
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Feb. 15	MT
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	Feb. 15	MT
Transcript : Organon & Co., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Organon: Q4 Earnings Snapshot	Feb. 15	AQ
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Organon & Co.

Equities

OGN

US68622V1061

Summary

Filters